ClearPoint Neuro, Inc. Stock

Equities

CLPT

US18507C1036

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 03:59:45 2024-05-29 pm EDT 5-day change 1st Jan Change
5.55 USD +0.73% Intraday chart for ClearPoint Neuro, Inc. -8.42% -18.26%
Sales 2024 * 30.52M Sales 2025 * 42.22M Capitalization 151M
Net income 2024 * -17M Net income 2025 * -16M EV / Sales 2024 * 4.95 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.58 x
P/E ratio 2024 *
-8.35 x
P/E ratio 2025 *
-8.89 x
Employees 107
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.06%
More Fundamentals * Assessed data
Dynamic Chart
Certain Common Stock of ClearPoint Neuro, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024. CI
Certain restricted stock units of ClearPoint Neuro, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024. CI
Certain stock options of ClearPoint Neuro, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024. CI
ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M MT
Transcript : ClearPoint Neuro, Inc., Q1 2024 Earnings Call, May 07, 2024
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory MT
ClearPoint Gets FDA Clearance For Neurosurgical Equipment MT
ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory CI
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System CI
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia MT
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M MT
More news
1 day-6.13%
1 week-9.23%
Current month+1.47%
1 month+4.75%
3 months-28.63%
6 months+1.85%
Current year-18.85%
More quotes
1 week
5.14
Extreme 5.135
6.26
1 month
5.14
Extreme 5.135
6.52
Current year
5.11
Extreme 5.105
7.97
1 year
4.05
Extreme 4.05
8.37
3 years
4.05
Extreme 4.05
22.80
5 years
2.86
Extreme 2.8601
31.29
10 years
1.33
Extreme 1.33
58.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 17-11-06
Director of Finance/CFO 39 20-09-28
Chief Operating Officer 44 22-10-09
Members of the board TitleAgeSince
Director/Board Member 72 19-08-31
Director/Board Member 64 21-07-14
Chairman 78 17-05-08
More insiders
Date Price Change Volume
24-05-29 5.55 +0.73% 130 150
24-05-28 5.51 -6.13% 517,573
24-05-24 5.87 -5.48% 149,957
24-05-23 6.21 +2.48% 210,535
24-05-22 6.06 -0.16% 182,475

Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT

More quotes
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.51 USD
Average target price
10 USD
Spread / Average Target
+81.49%
Consensus